Exposure of CLL cells to TLR9 agonists and IL-2 further enhances cAMP release in response to CGS21680, confirming that in activated CLLs the adenosinergic axis is boosted [2]. This evidence concerns the gene IL2 and B-cell chronic lymphocytic leukemia.